Sökning: WFRF:(Greinwald Roland)
> Lunds universitet >
Low-dose budesonide for maintenance of clinical remission in collagenous colitis : a randomised, placebo-controlled, 12-month trial
-
- Münch, Andreas (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Avdelningen för inflammationsmedicin,Hälsouniversitetet,Magtarmmedicinska kliniken,Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Gastroenterol & Hepatol, S-58185 Linkoping, Sweden.
-
- Bohr, Johan, 1957- (författare)
- Region Örebro län,Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden,Örebro University Hospital, and School of Health and Medical Sciences, Örebro University, Sweden,Univ Orebro, Orebro Univ Hosp, Dept Gastroenterol, SE-70182 Orebro, Sweden.;Univ Orebro, Sch Hlth & Med Sci, SE-70182 Orebro, Sweden.
-
- Miehlke, Stephan (författare)
- Centre for Digestive Disease, Hamburg, Germany,Ctr Digest Dis, Hamburg, Germany.
-
visa fler...
-
- Benoni, Cecilia (författare)
- Lund University,Lunds universitet,Anestesiologi och intensivvård,Forskargrupper vid Lunds universitet,Anaesthesiology and Intensive Care Medicine,Lund University Research Groups,University Hospital, Malmö, Sweden,Univ Hosp, Dept Gastroenterol, Malmo, Sweden.
-
- Olesen, Martin (författare)
- Department of Pathology, University Hospital, Malmö, Sweden,Univ Hosp, Dept Pathol, Malmo, Sweden.
-
- Öst, Åke (författare)
- Department of Pathology and Cytology, Aleris Medilab, Täby, Sweden,Aleris Medilab, Dept Pathol & Cytol, Taby, Sweden.
-
- Strandberg, Lars (författare)
- Regional Hospital, Falun, Sweden,Reg Hosp, Falun, Sweden.
-
- Hellström, Per M. (författare)
- Uppsala universitet,Gastroenterologi/hepatologi
-
- Hertervig, Erik (författare)
- Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,University Hospital, Lund, Sweden,Univ Lund Hosp, Dept Gastroenterol, S-22185 Lund, Sweden.
-
- Armerding, Peter (författare)
- Gastroenterology, Private Practice, Berlin, Germany
-
- Stehlik, Jiri (författare)
- Department of Gastroenterology, Regional Hospital, Usti nad Labem, Czech Republic,Reg Hosp, Dept Gastroenterol, Usti Nad Labem, Czech Republic.
-
- Lindberg, Greger (författare)
- Karolinska Institutet,Karolinska University Hospital Huddinge, Stockholm, Sweden,Karolinska Univ Hosp Huddinge, Ctr Digest Dis, Stockholm, Sweden.
-
- Björk, Jan (författare)
- Karolinska Institutet,Karolinska University Hospital Solna, Stockholm, Sweden,Karolinska Univ Hosp Solna, Ctr Digest Dis, Stockholm, Sweden.
-
- Lapidus, Annika (författare)
- Department of Gastroenterology, Ersta Hospital, Stockholm, Sweden,Ersta Hosp, Dept Gastroenterol, Stockholm, Sweden.
-
- Löfberg, Robert (författare)
- IBD Unit, Department of Gastroenterology, Sophiahemmet, Stockholm, Sweden,Sophiahemmet, Dept Gastroenterol, IBD Unit, Stockholm, Sweden.
-
- Bonderup, Ole (författare)
- Department of Gastroenterology, Regional Hospital, Silkeborg, Denmark,Reg Hosp, Dept Gastroenterol, Silkeborg, Denmark.
-
- Avnström, Sören (författare)
- Department of Gastroenterology, Amager Hospital, Copenhagen, Denmark,Amager Hosp, Dept Gastroenterol, Copenhagen, Denmark.
-
- Rössle, Martin (författare)
- Gastroenterology, Private Practice, Freiburg, Germany
-
- Dilger, Karin (författare)
- Dr Falk, Pharma GmBH, Freiburg, Germany
-
- Mueller, Ralph (författare)
- Dr Falk, Pharma GmBH, Freiburg, Germany
-
- Greinwald, Roland (författare)
- Dr Falk, Pharma GmBH, Freiburg, Germany
-
- Tysk, Curt, 1949- (författare)
- Region Örebro län,Department of Gastroenterology, Örebro University Hospital, Örebro, Sweden,Örebro University Hospital, and School of Health and Medical Sciences, Örebro University, Sweden,Univ Orebro, Orebro Univ Hosp, Dept Gastroenterol, SE-70182 Orebro, Sweden.;Univ Orebro, Sch Hlth & Med Sci, SE-70182 Orebro, Sweden.
-
- Ström, Magnus (författare)
- Linköpings universitet,Östergötlands Läns Landsting,Magtarmmedicinska kliniken,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Gastroenterol & Hepatol, S-58185 Linkoping, Sweden.
-
visa färre...
-
(creator_code:org_t)
- 2014-11-25
- Engelska.
-
Ingår i: Gut. - : BMJ Publishing Group. - 0017-5749 .- 1468-3288. ; 65:1, s. 47-56
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://gut.bmj.com/...
-
http://www.ncbi.nlm....
-
http://dx.doi.org/10...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: This 1-year study aimed to assess low-dose budesonide therapy for maintenance of clinical remission in patients with collagenous colitis.Design: A prospective, randomised, placebo-controlled study beginning with an 8-week open-label induction phase in which patients with histologically confirmed active collagenous colitis received budesonide (Budenofalk, 9 mg/day initially, tapered to 4.5 mg/day), after which 92 patients in clinical remission were randomised to budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days) or placebo in a 12-month double-blind phase with 6 months treatment-free follow-up. Primary endpoint was clinical remission throughout the double-blind phase.Results: Clinical remission during open-label treatment was achieved by 84.5% (93/110 patients). The median time to remission was 10.5 days (95% CI (9.0 to 14.0 days)). The maintenance of clinical remission at 1 year was achieved by 61.4% (27/44 patients) in the budesonide group versus 16.7% (8/48 patients) receiving placebo (treatment difference 44.5% in favour of budesonide; 95% CI (26.9% to 62.7%), p<0.001). Health-related quality of life was maintained during the 12-month double-blind phase in budesonide-treated patients. During treatment-free follow-up, 82.1% (23/28 patients) formerly receiving budesonide relapsed after study drug discontinuation. Low-dose budesonide over 1 year resulted in few suspected adverse drug reactions (7/44 patients), all non-serious.Conclusions: Budesonide at a mean dose of 4.5 mg/day maintained clinical remission for at least 1 year in the majority of patients with collagenous colitis and preserved health-related quality of life without safety concerns. Treatment extension with low-dose budesonide beyond 1 year may be beneficial given the high relapse rate after budesonide discontinuation.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
- Av författaren/redakt...
-
Münch, Andreas
-
Bohr, Johan, 195 ...
-
Miehlke, Stephan
-
Benoni, Cecilia
-
Olesen, Martin
-
Öst, Åke
-
visa fler...
-
Strandberg, Lars
-
Hellström, Per M ...
-
Hertervig, Erik
-
Armerding, Peter
-
Stehlik, Jiri
-
Lindberg, Greger
-
Björk, Jan
-
Lapidus, Annika
-
Löfberg, Robert
-
Bonderup, Ole
-
Avnström, Sören
-
Rössle, Martin
-
Dilger, Karin
-
Mueller, Ralph
-
Greinwald, Rolan ...
-
Tysk, Curt, 1949 ...
-
Ström, Magnus
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Gut
- Av lärosätet
-
Örebro universitet
-
Lunds universitet
-
Karolinska Institutet
-
Linköpings universitet
-
Uppsala universitet